TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6356326

Group type: EXPERIMENTAL
Intervention: Gastrointestinal hormones (VIP, motilin, enteroglucagon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucagon, enkephalins, somatostatin
Number of subjects: 0
Study: 31727580

Group type: EXPERIMENTAL
Intervention: Algorithm-guided empirical tuberculosis treatment
Number of subjects: 3022

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 3022
Study: 31240811

Group type: EXPERIMENTAL
Intervention: 12 weeks of at-home cessation support
Number of subjects: 404

Group type: COMPARATOR
Intervention: NICE PH48 care as usual
Number of subjects: 404
Study: 28452870

Group type: EXPERIMENTAL
Intervention: Time to MT protocol activation
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Time to delivery of first cooler
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Increased time to MT activation
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Increased time to arrival of first cooler
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Time to achieving hemostasis
Number of subjects: 680
Study: 25273547

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei subsp. paracasei L. casei W8® (1010 cfu daily) for four weeks
Number of subjects: 64
Study: 23783097

Group type: EXPERIMENTAL
Intervention: CDCA (5 mmol/L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CDCA (15 mmol/L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CDCA (5 or 15 mmol/L)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium oleate with 5 mmol/L CDCA
Number of subjects: 12
Study: 21856968

Group type: EXPERIMENTAL
Intervention: Teacher responsivity education intervention
Number of subjects: 330

Group type: COMPARATOR
Intervention: Business-as-usual control condition
Number of subjects: 330
Study: 19173181

Group type: EXPERIMENTAL
Intervention: (90)Y‐DOTATATE (7.4 GBq/m(2) cumulative dose)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: (90)Y‐ibritumomab tiuxetan (1200 MBq max dose)
Number of subjects: 62
Study: 16895488

Group type: EXPERIMENTAL
Intervention: Systemic warming using a disposable forced warm-air blanket
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conductive carbon polymer mattress and overblanket
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local warming with non-contact radiant heat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care without local warming
Number of subjects: 0
Study: 17163896

Group type: EXPERIMENTAL
Intervention: Nurses' knowledge of EBP
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nurses' beliefs about the benefits of EBP
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Having an EBP mentor
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Using the Cochrane Database of Systematic Reviews and the National Guideline Clearinghouse
Number of subjects: 160
Study: 11476298

Group type: EXPERIMENTAL
Intervention: Proximal row carpectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arthrodesis of the radiocarpal joint
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excision of the scaphoid combined with midcarpal arthrodesis
Number of subjects: 0
Study: 9372504

Group type: EXPERIMENTAL
Intervention: Triple dose (TD) gadolinium (0.3 mmol/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard dose (s.d.) gadolinium (0.1 mmol/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Delayed scanning (DS) after TD
Number of subjects: 15
Study: 7941662

Group type: EXPERIMENTAL
Intervention: QT-interval pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minute ventilation (MV) pacing
Number of subjects: 0
Study: 2975228

Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 30
Study: 29559344

Group type: EXPERIMENTAL
Intervention: Ustekinumab treatment
Number of subjects: 114
Study: 27475688

Group type: EXPERIMENTAL
Intervention: Oral ketorolac 10 mg plus intramuscular placebo (1 mL saline solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular tramadol 50 mg diluted in 1 mL saline solution plus oral placebo (similar tablet to oral ketorolac)
Number of subjects: 30
Study: 24047817

Group type: COMPARATOR
Intervention: Tetravalent vaccine and placebo
Number of subjects: 601

Group type: COMPARATOR
Intervention: A/H5N1 vaccine and placebo
Number of subjects: 601

Group type: COMPARATOR
Intervention: A/H5N1 and seasonal vaccines
Number of subjects: 601
Study: 23368891

Group type: EXPERIMENTAL
Intervention: Wire-guided biliary cannulation (WGC)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Conventional cannulation (CC)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Accidental guidewire insertions and unintended injections of contrast into the main pancreatic duct
Number of subjects: 322
Study: 20651217

Group type: EXPERIMENTAL
Intervention: Endurance training (12 weeks, 5 days/week, 1 hour/day at 65% Vo(2peak))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Endurance training (12 weeks)
Number of subjects: 10
Study: 18793563

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (conventional oral agents alone)
Number of subjects: 40
Study: 16802853

Group type: EXPERIMENTAL
Intervention: Ciclesonide (320 microg ex‐actuator; equivalent to 400 microg ex‐valve) via HFA‐MDI with AeroChamber Plus spacer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ciclesonide (320 microg ex‐actuator; equivalent to 400 microg ex‐valve) via HFA‐MDI without AeroChamber Plus spacer
Number of subjects: 30
Study: 12890927

Group type: EXPERIMENTAL
Intervention: Haplotype-environment interaction testing method
Number of subjects: 0
Study: 10615840

Group type: EXPERIMENTAL
Intervention: Experiencing at least one stressful life event during the periconceptional period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (women not experiencing stressful life events)
Number of subjects: 0
Study: 9239580

Group type: EXPERIMENTAL
Intervention: Hypothermic Group (T reduced to 32.0 degrees C)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control Group (T maintained at 35.5 degrees C)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 1586733

Group type: EXPERIMENTAL
Intervention: Prophylactic heparin 100 U/kg/d by continuous infusion from day -8 until day +30 post-BMT
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Prophylactic heparin after allogeneic BMT
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group after allogeneic BMT
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 161
Study: 3032827

Group type: EXPERIMENTAL
Intervention: Dietary fibre tablets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 60
Study: 29447076

Group type: EXPERIMENTAL
Intervention: Pork collagen peptide (CP) 2.5 g/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo 2.5 g/day
Number of subjects: 70
Study: 27007213

Group type: EXPERIMENTAL
Intervention: Infliximab with standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study: 24422726

Group type: EXPERIMENTAL
Intervention: 4-HNE-conjugates
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: AOPP
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: haemoglobin binding to RBC-membranes
Number of subjects: 349
Study: 22998182

Group type: EXPERIMENTAL
Intervention: Screening arm (radical prostatectomy)
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Control arm (radical prostatectomy)
Number of subjects: 1151
Study: 20003398

Group type: EXPERIMENTAL
Intervention: Cognitive activity intervention consisting of ten 90-minute sessions delivered twice per week over a period of five weeks.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-specific education (control group).
Number of subjects: 160
Study: 17312091

Group type: EXPERIMENTAL
Intervention: SS-QOL total score
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: SS-QOL observable scales (e.g., activities)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: SS-QOL subscales (energy, mood, thinking)
Number of subjects: 307
Study: 15334426

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 50 mg twice daily
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg twice daily
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg twice daily
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg twice daily
Number of subjects: 583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study: 11264762

Group type: EXPERIMENTAL
Intervention: Standardized commercial formula
Number of subjects: 17

Group type: COMPARATOR
Intervention: Blenderized formula
Number of subjects: 17
Study: 9884846

Group type: EXPERIMENTAL
Intervention: High-volume, low-pressure cuff at various airway pressures (10, 15, 20, 25, 30 cm H2O)
Number of subjects: 61
Study: 7983513

Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 2735156

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program for pain management (12 sessions of about 90 min each)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Waiting-for-treatment control group
Number of subjects: 25
Study: 1101762

Group type: EXPERIMENTAL
Intervention: Breathing 100 ppm of carbon monoxide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Compressed, purified air
Number of subjects: 10
Study: 30672339

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28211216

Group type: EXPERIMENTAL
Intervention: eplerenone 50 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study: 25839089

Group type: EXPERIMENTAL
Intervention: Nonthermal therapeutic ultrasound
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 30
Study: 24063830

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus atorvastatin 10 mg (Period I)
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus atorvastatin 20 mg (Period II)
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus atorvastatin 10 mg (Period I) or atorvastatin 20 mg (Period II)
Number of subjects: 1547

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 1547

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 1547

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 1547
Study: 21442811

Group type: EXPERIMENTAL
Intervention: Early acupuncture combined with exercise therapy; Xingnao Kaiqiao needling method applied at Shuigou (GV 26), Baihui (GV 20), Neiguan (PC 6) after vital signs stabilized.
Number of subjects: 455

Group type: COMPARATOR
Intervention: Conventional medicine and/or surgery without rehabilitation therapy (control group).
Number of subjects: 455
Study: 18851764

Group type: EXPERIMENTAL
Intervention: Implementation intentions (if-then plans)
Number of subjects: 0
Study: 22293088

Group type: EXPERIMENTAL
Intervention: Long acting parenteral oxytetracycline
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Long acting parenteral enrofloxacin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Topical application of potassium permanganate solution
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Parenteral antibacterials (oxytetracycline or enrofloxacin) for chronic footrot
Number of subjects: 92
Study: 15945202

Group type: EXPERIMENTAL
Intervention: Group D (one label for one color and one shape, another label for the other cues)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group S (one label for both colors and another for both shapes)
Number of subjects: 0
Study: 14597211

Group type: EXPERIMENTAL
Intervention: Allergen + DEP nasal challenge
Number of subjects: 18

Group type: COMPARATOR
Intervention: Allergen/placebo nasal challenge
Number of subjects: 18
Study: 10363918

Group type: EXPERIMENTAL
Intervention: With attention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Without attention
Number of subjects: 12
Study: 8521432

Group type: EXPERIMENTAL
Intervention: Annual application of APF gel with prior dental prophylaxis
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Biannual application of APF gel with prior dental prophylaxis
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Annual application of APF gel without prior dental prophylaxis
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Biannual application of APF gel without prior dental prophylaxis
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Prior dental prophylaxis
Number of subjects: 329

Group type: COMPARATOR
Intervention: No prior dental prophylaxis
Number of subjects: 329
Study: 2081143

Group type: EXPERIMENTAL
Intervention: Gallopamil (50 micrograms/kg over 5 minutes)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 160860

Group type: EXPERIMENTAL
Intervention: Ovral
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norinyl 1/50
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norlestrin
Number of subjects: 0
Study: 27702799

Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg with dexamethasone 40 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ixazomib 5.5 mg with dexamethasone 40 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall (both doses of ixazomib)
Number of subjects: 70
Study: 26242119

Group type: EXPERIMENTAL
Intervention: Transvaginal aspiration of hydrosalpinx combined with auricular point sticking (Group A)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Transvaginal aspiration of hydrosalpinx (Group B)
Number of subjects: 229

Group type: COMPARATOR
Intervention: No transvaginal aspiration of hydrosalpinx (Group C)
Number of subjects: 229
Study: 23801607

Group type: EXPERIMENTAL
Intervention: Tailored therapy regimen (amoxicillin, rabeprazole, and clarithromycin or metronidazole based on mutation detection)
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Standard triple therapy (amoxicillin, rabeprazole, and clarithromycin) in APC control group
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Standard triple therapy (amoxicillin, rabeprazole, and metronidazole) in APM control group
Number of subjects: 1232
Study: 21120255

Group type: EXPERIMENTAL
Intervention: Test antioxidant regimen (facial wash, day lotion, night crème, eye serum)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control regimen (control facial wash, control moisturizer)
Number of subjects: 40
Study: 18477782

Group type: EXPERIMENTAL
Intervention: Combined mammography plus ultrasound
Number of subjects: 2637

Group type: COMPARATOR
Intervention: Mammography alone
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Ultrasound alone
Number of subjects: 2637

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 2637
Study: 16920894

Group type: EXPERIMENTAL
Intervention: Single oral dose of 200 mg telbivudine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg telbivudine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single oral dose of 800 mg telbivudine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Repeat doses of 600 mg/d telbivudine
Number of subjects: 42
Study: 12637839

Group type: EXPERIMENTAL
Intervention: Intensive psychiatric community care (IPCC)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Baseline work
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Well-implemented IPCC programs
Number of subjects: 520
Study: 10960377

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 16
Study: 9007148

Group type: EXPERIMENTAL
Intervention: Laparoscopy (18 patients)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Laparotomy (20 patients)
Number of subjects: 38
Study: 1510353

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 6344983

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Adriamycin + DTIC
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Leiomyosarcomas
Number of subjects: 240
Study: 30446002

Group type: EXPERIMENTAL
Intervention: Allopurinol dose > CrCL-based dose (R+)
Number of subjects: 132
Study: 27560013

Group type: EXPERIMENTAL
Intervention: Fast acquisition protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow acquisition protocol
Number of subjects: 0
Study: 24816725

Group type: EXPERIMENTAL
Intervention: MGN1703 60 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 22288389

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with fractional laser therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fractional laser therapy alone
Number of subjects: 22
Study: 20094802

Group type: EXPERIMENTAL
Intervention: Fiber with insoluble 84% polyphenols 4 g twice a day (n = 43)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (n = 45)
Number of subjects: 88
Study: 17941096

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 70
Study: 16382297

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 53
Study: 12937331

Group type: EXPERIMENTAL
Intervention: Family therapy and technology-based intervention
Number of subjects: 225

Group type: COMPARATOR
Intervention: Minimal support control condition
Number of subjects: 225

Group type: COMPARATOR
Intervention: Structural ecosystems therapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Structural ecosystems therapy + computer-telephone integrated system
Number of subjects: 225
Study: 12131543

Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 754

Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 754
Study: 10403596

Group type: EXPERIMENTAL
Intervention: Licensed influenza vaccine
Number of subjects: 139

Group type: COMPARATOR
Intervention: Subpotent influenza vaccine
Number of subjects: 139
Study: 7825615

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (2.2 mmol/L)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Epinephrine, norepinephrine, cortisol, growth hormone, glucagon levels measured at each glucose plateau
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (21.1 mmol/L)
Number of subjects: 42
Study: 2245457

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 48
Study: 7010529

Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30644838

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Polarized light microscopy (PLM)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 1% sucrose and S mutans model
Number of subjects: 168
Study: 28314604

Group type: EXPERIMENTAL
Intervention: Double-balloon colonoscopy (DBC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 44
Study: 26212372

Group type: EXPERIMENTAL
Intervention: Hypoxia training (∼ 3300 m)
Number of subjects: 14
Study: 24103561

Group type: EXPERIMENTAL
Intervention: Dialysis treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement protocol including polysomnography and specific questionnaires
Number of subjects: 0
Study: 20528209

Group type: EXPERIMENTAL
Intervention: Endometrial trauma during embryo transfer trials (ETTs) performed on day 21 of the previous cycle
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Endometrial trauma during embryo transfer trials (ETTs) performed on day 6 of the controlled ovarian hyperstimulation (COH) cycle
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Endometrial trauma during embryo transfer trials (ETTs) conducted at least two cycles before COH cycle
Number of subjects: 150
Study: 19148113

Group type: EXPERIMENTAL
Intervention: Intervention involving parents (e.g., parent education, infant stimulation, home visits, individualized developmental care)
Number of subjects: 2198

Group type: EXPERIMENTAL
Intervention: Intervention involving parents
Number of subjects: 2198
Study: 17942775

Group type: EXPERIMENTAL
Intervention: Disruption of fibrin sheaths via angioplasty
Number of subjects: 47

Group type: COMPARATOR
Intervention: No disruption of fibrin sheaths
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: No sheaths present
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sheaths present and not disrupted
Number of subjects: 47
Study: 15547184

Group type: EXPERIMENTAL
Intervention: Four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Locoregional treatment alone (group B)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) among operable patients
Number of subjects: 237

Group type: COMPARATOR
Intervention: Locoregional treatment alone (group B) among operable patients
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) among inoperable patients
Number of subjects: 237

Group type: COMPARATOR
Intervention: Locoregional treatment alone (group B) among inoperable patients
Number of subjects: 237
Study: 11535479

Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg IM or 2.5 mg IV)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Prochlorperazine (10 mg IM or 10 mg IV)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 168

Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 168
Study: 9481998

Group type: EXPERIMENTAL
Intervention: Indomethacin phonophoresis (1% indomethacin cream with ultrasound massage at 1.0 MHz, 0.8 to 1.5 W/cm2 for 15 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo cream with ultrasound massage (1.0 MHz, 0.8 to 1.5 W/cm2 for 15 minutes)
Number of subjects: 20